Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Dave Coulier has revealed that he developed near-fatal cold during his cancer treatment. The actor, best known for his role ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Another difference is that non-Hodgkin lymphoma can form in lymph nodes all over your body ... your doctor may order a series of imaging tests to determine how to go about treatment. Dr. Jakub Svoboda ...

These keywords underscore the application of PET/CT in diagnosis, treatment monitoring ... The second group covered Diffuse Large B-Cell Lymphoma (#1), MALT Lymphoma (#5), and Non-Hodgkin’s Lymphoma ( ...

The German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) B-ALL/NHL 2002 protocol achieved a 3-year overall survival and progression-free survival of 73% in adult patients ...

2–4 In this study, patients were evaluated using PET after two cycles of assigned treatment (PET-2) and completed either four or six cycles of treatment, depending on the PET-2 results. Is it ...

In the HD21 trial, even in the small, but presumably very high-risk group of patients who were PET-2 positive with persistent PET-positive residual disease at the end of treatment with BrECADD (ie, 74 ...

Imaging and histological investigations revealed a primary Non-Hodgkin’s Lymphoma located in the infra-temporal ... PET-CT are now considered gold standards for staging and assessing treatment ...

From the 2nd April 2025, adults with advanced Hodgkin lymphoma will have access to a new treatment called brentuximab vedotin (brand name Adcetris) combined with other therapies. Hodgkin lymphoma is a ...